Owkin signs AI drug discovery deal with Boehringer for cancer, immunology

Owkin signed a licensing deal with Boehringer Ingelheim to give the drugmaker access to Owkin’s AI research platform and patient data. The partnership is intended to accelerate drug discovery for cancer and immunity-related diseases, supporting Owkin’s platform commercialization efforts. Impact is likely modest near-term absent deal financial terms, but it is a positive validation signal for the business.